Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Scientists test new drug cocktail in fight against tough pancreatic cancer

NCT ID NCT00885066

Summary

This early-stage study tested a combination of three drugs—gemcitabine, capecitabine, and erlotinib—in patients with advanced pancreatic cancer that had worsened after initial treatment. The main goal was to find the highest dose patients could tolerate without severe side effects. Researchers also wanted to understand how the drugs interact in the body.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Centre Antoine Lacassagne

    Nice, 06189, France

Conditions

Explore the condition pages connected to this study.